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Background: Alterations of B cell subset distribution have been described in the peripheral blood (PB) of
rheumatoid arthritis (RA) patients, but no data are available on differences between the onset and the established
phases of the disease. The purpose of the study was to clarify whether a peculiar distribution of B cell subsets
characterizes RA onset, thus leading to a more favorable clinical response to treatment, and to evaluate the
possible association of a particular B cell subpopulation with response to therapy.
Results: 122 RA patients were enrolled: 25 had symptom duration less than 3 months and were defined as having
“very early RA” (VERA), and 43 had symptom duration from more than 3 months up to one year (early-RA: ERA).
The other 54 RA patients had long-standing RA (LSRA). At baseline and at 6-month follow-up visit peripheral blood
samples were collected and analyzed by flow cytometry for the distribution of circulating B cell subsets by staining
with surface markers CD45, CD19, CD38, CD27 and IgD and intracellular marker ZAP70.
VERA and ERA patients showed higher percentages and absolute counts of circulating antigen inexperienced naïve
B cells (IgD + CD27-) and lower percentages and absolute numbers of double negative (IgD-CD27-) memory B cells
and plasmablasts (CD38 + CD27+) compared to LSRA patients. At the multivariate analysis, a higher frequency of
naïve B cells (IgD + CD27-) at baseline arose as significant predictor of CDAI remission, together with “having VERA
disease” and a low disease activity at baseline.
Conclusions: The onset of RA is characterized by higher percentages and absolute numbers of naïve B cells and
lower numbers of plasmablasts and double negative memory B cells compared to established RA. Naïve B cells
could represent a promising biomarker of outcome.
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In the last years, B cells have been shown to play a key
role in the pathogenesis of rheumatoid arthritis (RA), as
suggested by rheumatoid factor (RF) and anti-citrullinated
peptide antibody (ACPA) positivity as marker of disease
severity that may precede the onset of symptoms by
many years [1-4]; moreover, B cell depletion therapy has
proven to be effective in seropositive patients [5]. Be-
sides the production of autoantibodies, B cells act as
antigen-presenting cells and secrete pro-inflammatory* Correspondence: gf.ferraccioli@rm.unicatt.it
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unless otherwise stated.cytokines, such as interleukin-6 (IL-6), tumor necrosis
factor (TNF) and interleukin-1 [6,7].
The elevation of B cell activation markers, such as
beta2-microglobulin, immunoglobulin levels, free light
chains of immunoglobulins and B-cell activating factor
(BAFF) at the onset of RA highlights that B cells are in-
volved in the early pathogenetic phases of the disease [8,9].
Alterations of B cell subset distribution have been de-
scribed in the peripheral blood (PB) of RA patients. In
long-standing RA (LSRA), an increased frequency of
post-switch IgD-CD27+ memory B cells was found
[10,11], while a lower frequency of pre-switch IgD +Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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after anti-TNF therapy [11].
To date, few data are available regarding the B cell sub-
set distribution at the beginning of RA. It is well known
that a clinical “window of opportunity” exists (<12 weeks
symptoms) for RA, since an early intervention may alter
the propensity to persistence and therefore offer the op-
portunity of reaching remission [12]. There is a great need
for biomarkers that can help the physicians to understand
the pathogenetic mechanisms underlying this “therapeutic
window”. Among these biomarkers, B cell subsets may be
key drivers involved in the early phases of the disease.
Recently, a lower percentage of circulating total mem-
ory B cells and a significant decrease in the frequency of
pre-switch antigen experienced memory B cells (IgD +
CD27+) were described in RA patients with a disease
duration less than six weeks as compared with controls
[13]. No data are available on plasmablasts or double
negative memory B cells.
Besides studying B cell surface markers, it is interest-
ing to evaluate whether there is an imbalance in the
intracellular activation markers of B lymphocytes, such
as Zeta-chain-associated protein kinase 70 (ZAP-70).
ZAP-70 is a protein kinase that is directly involved in
the T cell signaling. Moreover, ZAP-70 has been shown
to be expressed in some activated B cell subsets. We
have demonstrated that B cells from the synovial com-
partment of RA patients express higher levels of ZAP-70
compared to B cells from patients with osteoarthritis
and positively correlate with the synovial levels of auto-
antibodies, IL-6 and BAFF [14]. The functional signifi-
cance of ZAP-70 in B-cell activation remains poorly
documented. Recently, it has been proposed that B cell
migration in vivo through the inflammatory sites is dir-
ectly linked to a ZAP-dependent pathway mediated by
the CXCR4/CD74 axis [15].
The aim of the study was to test the hypothesis that a
different distribution of circulating memory B cells, plas-
mablasts and B cell activated subsets (i.e. CD19+/ZAP-
70+ B cells) in early compared to long-standing RA could
lead to a more favorable clinical response to treatment,
and to evaluate whether the distribution of B cell subpop-
ulations correlates with disease activity, particularly with
the inflammatory milieu, at the onset of the disease. Fi-
nally, we examined whether B cell subset distribution at
baseline could predict, as a biomarker, the clinical re-
sponse at 24 weeks of follow-up in a treat to target strat-
egy, and could be modified by conventional treatment in
patients with RA at onset.
Methods
Patients
Peripheral blood samples from 122 RA patients and 30
healthy subjects, matched for age and sex, were collectedfor flow cytometric analysis. The ethical approval for the
study was obtained from the Catholic University of the
Sacred Heart Ethical Committee and all participants
gave informed consent.
All RA patients fulfilled the 1987 and 2010 American
College of Rheumatology (ACR) criteria for RA [16,17].
Sixty-eight of the 122 RA patients had symptom dur-
ation less than 12 months, of which 25 (36.8%) subjects
with symptom duration less than 3 months were defined
as having “very early RA (VERA)” [18]. The remaining
43 patients had symptom duration from more than
3 months up to one year (early-RA: ERA). Both VERA
and ERA patients were naïve to disease-modifying anti-
rheumatic drugs (DMARDs) and/or anti-TNF drugs at the
time of enrollment.
VERA and ERA patients were followed every month
up to three months and every three months thereafter.
At each visit the ACR/ European League Against Rheuma-
tism (EULAR) core data set (erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), swollen joint count
(SJC), tender joint count (TJC), physician and patient
global assessment, pain, health assessment questionnaire
(HAQ)) was registered and DAS was calculated [19].
At baseline, VERA and ERA patients were treated with
methotrexate (up to 20 mg weekly) and, when necessary,
with a low steroid dose for three months; then a com-
bination with a TNF blocker (adalimumab 40 mg every
two weeks, or etanercept 50 mg weekly) was started if
patients did not reach at least a good response according
to EULAR criteria (DAS44: DAS ≤2.4) [20]. At each visit,
clinical improvement and remission were evaluated ac-
cording to DAS [20,21] and CDAI cut-off points [22].
The other 54 RA patients had a long-standing disease
(LSRA; mean disease duration of 12.5 ± 7.9 years). LSRA
patients were consecutively selected from RA out-patients
who had an active disease (DAS > 2.4) despite being on
treatment with one or more DMARDs and/or anti-TNF
drugs.
Flow cytometry and immunophenotyping of B cells
PB samples were collected at baseline from 122 RA pa-
tients and at 6-month follow-up visit from 61 RA patients
and immunofluorescence labelling for flow cytometric
analysis of circulating B cell subpopulations was per-
formed by incubating 100 μl of PB with anti-human
monoclonal antibodies. Cells were stained with anti-
human antibodies specific for CD45 (APC-A750), CD19
(APC-700), CD3 (ECD), CD56 (ECD), CD38 (PC5 or
APC), CD27 (PC7) and FITC-conjugated IgD (Beckman
Coulter, Marseille France). After 20 minutes of incuba-
tion, the samples were fixed with 200 μl of Reagent 1
(Beckman Coulter, Marseilles, France) for 15 minutes at
room temperature (RT) in the dark. After washing, the
pellet was incubated with 200 μl of Reagent 2 (Beckman
Table 1 Demographic and clinical characteristics of RA
patients (VERA, ERA and LSRA) at the study entry
Variables VERA ERA LSRA
N. 25 43 54
Age, years 57.5 ± 13.0 50.4 ± 14.9 53.0 ± 13.7
Sex, n. female, (%) 21 (84.0) 38 (88.4) 45 (86.5)
ESR, mm/1^hour 51.4 ± 33.7 39.1 ± 28.6 39.6 ± 23.8
CRP, mg/l 29.9 ± 45.5 16.2 ± 25.3 20.3 ± 28.0
DAS 3.7 ± 1.1 3.3 ± 1.0 3.7 ± 1.4
ACPA positivity, n. (%) 12 (48.0) 28 (65.1) 37 (72.5)
RF-IgM positivity, n. (%) 12 (48.0) 25 (58.1) 28 (54.9)
RF-IgA positivity, n. (%) 7 (28.0) 17 (39.5) 16 (31.4)
Values are mean ± standard deviation unless otherwise indicated. ERA: early
rheumatoid arthritis; LSRA: long-standing rheumatoid arthritis; VERA: very early
rheumatoid arthritis; ESR: erythrocyte sedimentation rate; CRP: C-reactive
protein; DAS: disease activity score; ACPA: anti-citrullinated peptide antibodies;
RF: rheumatoid factor.
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the dark. The samples were then incubated with PE-
conjugated ZAP-70 specific AB (clone SBZAP, Beckman
Coulter, Marseilles, France) for 30 minutes at RT in the
dark. After staining, the cells were washed and immedi-
ately analyzed on properly compensated 8 colors Navios
flow-cytometer and data were elaborated with the Kaluza
program (Beckman Coulter, Marseille, France). Lympho-
cytes were gated on the basis of forward-and side-scatter
properties (confirmed through CD45 staining) and at least
10,000 CD19+ cells were analyzed. B cell subsets were
evaluated through the expression of surface B cell markers
according to IgD/CD27 classification [23].
The expression of ZAP-70 on CD19+ cells was mea-
sured according to the gating strategy published by Crespo
et al. [24]. B cells were defined as CD56 and CD3 negative
and CD19 positive cells. The percentage of ZAP-70
positive B cells was evaluated at 98% of ZAP-70 positiv-
ity of T-NK cells [25].
Detection of Autoantibodies
RF-IgM and RF-IgA (Orgentec Diagnostika GmbH, Mainz,
Germany), ACPA (Axis Shield Diagnostics, Dundee, UK)
and anti-mutated citrullinated vimentin (MCV) (Or-
gentec Diagnostika, Dundee, UK) were measured using
commercial ELISA and performed according to the
manufacturer’s instruction. The suggested cut-off levels
were 20 U/ml for RF-IgM, RF-IgA and anti-MCV and
5 U/ml for ACPA.
Soluble biomarkers
Blood samples were collected from all patients at base-
line and from VERA and ERA patients six months after
starting therapy. Samples were immediately centrifuged
and stored at −80°C until analysis. Plasma levels of IL-6
and BAFF were measured by ELISA (R&D Systems, UK).
The sensitivity of the test was of 2.2 pg/ml for IL-6 and
2.4 pg/ml for BAFF.
Statistical analysis
Statistical analysis was performed using SPSS (SPSS ver-
sion 16.0, Chicago, IL, USA) and Graph-Pad Prism stat-
istical software (San Diego, CA, USA). Categorical and
quantitative variables were recorded as frequencies,
percentage, mean ± Standard Deviation (SD). The non-
parametric Mann–Whitney U test was used to compare
the continuous variables. Categorical variables were an-
alyzed using χ2 test or the Fisher’s exact test.
The Spearman rank correlation was used to evaluate
the relationship between the different B cell subsets and
between B cell subsets and inflammatory and clinical pa-
rameters and the Wilcoxon test was used to compare
the B cell subpopulations and soluble biomarkers during
follow-up in the VERA and ERA cohort. A receiveroperating characteristic (ROC) analysis of the continu-
ous parameters related to the response to therapy was
performed by plotting the relationship between sensitiv-
ity, on the y-axis, and 1-specificity, on the x-axis, for dif-
ferent cut-off levels of test positivity. The area under the
ROC curve (ROC AUC) provides a measure of the overall
discriminative ability of a model. The ROC area and its
standard error (SE) were estimated using the nonpara-
metric approach. The optimal cut-off point was deter-
mined to yield the maximum corresponding sensitivity
and specificity.
The variables related to response to therapy in VERA and
ERA patients with a p ≤ 0.15 at the univariate analysis en-
tered into a multivariate logistic regression model in which
“DAS remission or CDAI remission at 24 week follow-up
visit” was the variable to be explained. Results are expressed
as the odds ratio (OR) and 95% confidence interval (95%
CI). Statistical significance was defined as p <0.05.Results
Characteristics of the study populations
There were no differences in demographic, clinical and
immunological parameters between patients with VERA,
ERA and LSRA. Each cohort had a moderate-severe dis-
ease at study entry and no difference was seen between
groups (DAS: 3.7 ± 1.1 in VERA, 3.3 ± 1.0 in ERA and
3.7 ± 1.4 in LSRA patients) (Table 1).
At study entry, 4 VERA (16.0%) and 9 ERA (20.9%)
patients had already been treated with low doses of cor-
ticosteroids (less than 10 mg of prednisone daily).
Among patients with LSRA, 24 (44.4%) were taking
DMARDs, while a combination therapy with anti-TNF
was administered to 30 (55.6%) of them.
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disease duration
VERA and ERA patients showed similar percentages of
CD19+ cells (VERA: 10.1 ± 4.5%; ERA: 9.8 ± 4.2%), gated
on total lymphocytes, with controls (9.5 ± 2.6%) but sig-
nificantly higher compared to LSRA patients (6.9 ± 4.2%,
p = 0.002 vs VERA and p = 0.001 vs ERA). There were
no differences in the absolute B cell number between
the three analyzed cohorts (data not shown).
Lower frequency and absolute count of double negative
memory B cells and plasmablasts in VERA and ERA
compared to LSRA patients
We analyzed the main B cell subsets, according to their
IgD and CD27 expression [23]. The frequency and total
count number of antigen inexperienced naïve B cells
(IgD + CD27-), antigen experienced pre-switched mem-
ory B cells (IgD + CD27+), post-switched memory B
cells (IgD-CD27+), double negative memory B cells
(IgD-CD27-) and CD27 + CD38+ B cells from VERA
and ERA patients were compared to LSRA patients.Figure 1 Distribution of the percentage of the different B cell subsets
IgD and CD27 classification. Plots represent the percentage of IgD + CD2
cells (D).Similar percentages and absolute count of B cell sub-
sets were observed in VERA and ERA patients (Figure 1,
Additional file 1: Table S1 and Additional file 2: Figure
S1) and controls. The naïve B cell subset (IgD + CD27-)
(both percentage and absolute count) was increased sig-
nificantly in both VERA and ERA patients compared to
patients with LSRA, whereas the percentage and abso-
lute count of IgD-CD27- B cells was lower in VERA and
ERA patients compared to LSRA (Figure 1B and 1D,
Additional file 1: Table S1 and Additional file 2: Figure S1).
Moreover, the frequency and number of CD19+/CD27 +
CD38+ cells were lower in VERA and ERA patients com-
pared to LSRA patients (Figure 2, Additional file 1: Table
S1 and Additional file 2: Figure S1).
These data suggest that the early phases of RA are
characterized by an expansion of naïve-activated B cell
subset and a lower frequency and number of double nega-
tive memory B cells and plasmablasts compared to the
later stages of the disease.
No differences were found in B cell subset distribution
dividing patients according to demographic parameters,in patients with VERA, ERA and LSRA patients, according to the
7+ cells (A), IgD + CD27- cells (B), IgD-CD27+ cells (C) and IgD-CD27-
Figure 2 Percentage of circulating CD38 + CD27+ B cells in
VERA, ERA RA and LSRA patients.
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oid therapy in VERA and ERA patients at baseline.
Finally, the B cell subset distribution was similar ac-
cording to the different therapeutic strategies in LSRA
patients (data not shown).
Plasma BAFF and IL-6 levels differ between RA at onset
and established RA
Plasma BAFF levels were significantly higher in both
VERA (p = 0.002) and ERA patients (p < 0.001) compared
to LSRA patients (Figure 3A), whereas plasma IL-6 levels
where higher in the VERA cohort when compared to
LSRA subjects (p = 0.03) (Figure 3B). No difference was
seen in plasma BAFF and IL-6 levels between VERA and
ERA patients.
In VERA and ERA patients, plasma BAFF and IL-6
levels at baseline were not influenced by demographicFigure 3 Plasma BAFF (A) and IL-6 (B) levels in VERA, ERA and LSRA p
data.parameters and corticosteroid use. Moreover, plasma
levels of IL-6 and BAFF were similar in the subgroup of
LSRA, independently from the different therapeutic
strategies (data not shown).
Correlations between plasma BAFF and IL-6 levels and B
cell subsets in VERA and ERA patients
In VERA and ERA patients, plasma BAFF levels directly
correlated with naïve B cell (IgD + CD27-, r = 0.31, p =
0.01), plasmablast (r = 0.26, p = 0.05) and memory IgD-
CD27- B cell (r = 0.31, p = 0.01) frequencies, and in-
versely correlated with unswitched- (IgD + CD27+: r =
0.41, p = 0.001) and switched- (IgD-CD27+: r = 0.33, p =
0.01) memory B cell frequencies.
There were no significant correlations between plasma
IL-6 levels and the different B cell subsets, in the three
cohorts of RA patients (data not shown).
ZAP-70 expression in B cells of VERA, ERA and LSRA
patients
The percentage and absolute number of B cells expressing
intracellular ZAP-70 were similar in the three analyzed
cohorts of RA patients (Additional file 1: Table S1), but
higher than in healthy controls (1.8 ± 0.9% , p = 0.001 vs
VERA, p = 0.002 vs ERA and p = 0.04 vs LSRA).
As noted in an our recent work [25], ZAP-70+ B cells
show a phenotype belonging to the memory pool [IgD +
CD27+ (p = 0.003), IgD-CD27+ (p < 0.001) and IgD-
CD27- (p < 0.001)] when compared to the ZAP-70 nega-
tive ones (Additional file 3: Figure S2).
As expected, the percentage of circulating ZAP-70+ B
cells directly correlated with the percentages of plasma-
blasts (r = 0.32, p = 0.01) and of double negative memory
B cells (r = 0.37, p = 0.002), in VERA and ERA patients.atients. The Mann–Whitney test was used for comparison of unpaired
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the number (r = 0.35, p = 0.01) of circulating CD19+/ZAP-
70+ cells directly correlated with plasma BAFF levels.
Disease activity and B cell subset distribution in VERA
and ERA patients at baseline
VERA and ERA patients with a severe disease at baseline
(DAS >3.7) showed lower percentages of CD19+ cells
(8.4 ± 4.0%) compared to subjects with a low-moderate
disease activity (DAS < 3.7) (11.2 ± 4.4%, p = 0.02) and
higher percentages and numbers of CD19+/CD27 +CD38+
(CD19+/CD27 + CD38+ (%): 4.4 ± 5.9% vs 1.2 ± 1.1%,
p = 0.004 and CD19+/CD27 + CD38+ cells/μl: 7.2 ± 15.2
vs 3.2 ± 4.7 cells/μl; p = 0.04). We found no correlation
between disease activity at baseline and the other B cell
subsets, both in number and percentage (data not
shown).
Baseline predictive factors associated with response to
therapy at 24 week follow-up visit in VERA and ERA
patients
Forty-five out of 61 VERA and ERA patients (73.8%)
were classified as good EULAR responders, while 32
(52.5%) were in DAS remission (DAS < 1.6) and 20 (32.8%)
in CDAI-remission (CDAI ≤ 2.8) at 24 week follow-up visit.
Seven VERA and ERA patients were lost during follow-up.
At 24 weeks of follow-up, 17 (27.9%) patients were in
combination therapy with anti-TNF drugs, while the
other 44 patients were in monotherapy with DMARDs
(72.1%). The remission rate was similar in patients
treated with DMARDs (DAS remission: 50.0%, CDAI re-
mission: 27.3%) and anti-TNF drugs (DAS remission:
58.8%, p = 0.54; CDAI remission: 47.1%, p = 0.14) at
24 week follow-up visit.
The baseline disease characteristics and the B cell sub-
set distribution were, first, analyzed in correlation with
DAS remission at 24 weeks. By univariate analysis, youn-
ger age, lower inflammatory markers and lower disease
activity, a higher frequency of naïve B cells (IgD +CD27-)
and a lower frequency of switched-memory B cells
(IgD-CD27+) were associated with DAS remission and
subsequently included in the multivariate analysis. At
the multivariate analysis, a younger age at diagnosis (OR
(95% CI): 0.92 (0.87-0.97)) and a higher frequency of
naïve B cells (IgD + CD27-) (OR(95% CI): 1.06 (1.01-
1.11)) were significantly associated with DAS remission
at 24 weeks of follow-up (Table 2). A more stringent
definition of remission (i.e. CDAI remission) was evalu-
ated in the same cohort of patients. At the multivariate
analysis, “having VERA disease” (OR(95% CI): 8.89 (1.79-
44.20)) and a low disease activity at baseline (OR(95% CI):
0.34 (0.14-0.83)) arose as significant predictors of CDAI
remission together with a higher frequency of naïve B cells
(IgD +CD27-) at baseline (OR(95% CI): 1.09 (1.02-1.17)).When DMARD users were selected (n = 44), “having
VERA disease” (OR(95% CI): 8.05 (1.16-55.99)) together
with a higher frequency of naïve B cells (IgD +CD27-) at
baseline (OR(95% CI): 1.09 (1.01-1.17)) were confirmed as
the independent variables associated with CDAI remission.
We next performed ROC analyses for the circulating
percentage of naïve B cells (IgD + CD27-) to predict re-
mission (both DAS remission and CDAI remission) at
the 24 weeks follow-up. The areas under the ROC curve
(AUCs) were 0.743 ± 0.074 for DAS remission and 0.695 ±
0.092 for CDAI remission, which are at the fair to good
threshold. Considering the CDAI remission, the sensitivity
and specificity (cut-off value: 60.0%) were 75.0% and 53.0%,
respectively.
Patients with circulating IgD + CD27- B cells at base-
line > 60.0% had 4 times higher chances of reaching re-
mission than patients with lower percentages [(OR(95%
CIs): 4.2 (1.2-14.7)].
The multivariate analysis was not performed in the
subgroup of anti-TNF treated patients due to the limited
number of cases (n = 17).
Influence of conventional therapy on clinical and
inflammatory parameters and B cell subset distribution
over time in VERA and ERA patients
Considering the subgroup of VERA and ERA patients
treated with DMARDs, a reduction of the inflammatory
biomarkers and disease activity was observed at 24 week
follow-up visit, together with a significant decrease of
RF-IgM and RF-IgA titers (Additional file 4: Table S2).
No difference was seen in B cell subsets over time (both
percentage and absolute number), both in patients
reaching remission, defined as DAS < 1.6 or CDAI ≤ 2.8
and in those not responding to therapy. The low number
of patients receiving anti-TNF agents forbids a definite
conclusion, even though treatment with anti-TNF
seemed to reduce the percentage of CD19+/ZAP70+
cells at 24 weeks (8.4 ± 9.5% at baseline vs 3.7 ± 2.6% at
24 weeks, p = 0.04) in VERA and ERA patients (n = 17).
Discussion
To date few data are available regarding the distribution
of circulating B cell subsets in the early phases of RA.
The aim of our study was to examine whether there
could be a peculiar B cell subset distribution in the PB
of patients with RA at onset compared to long-standing
RA and to evaluate a possible association of B cell sub-
populations with response to therapy.
In this study, we observed significant differences in the
distribution of circulating B cell subsets, both in absolute
number and percentage, between VERA and ERA com-
pared to LSRA patients. Analyzing in detail the different
B cell subsets, VERA and ERA patients showed higher
percentages and numbers of antigen inexperienced naïve
Table 2 Baseline demographic, clinical and immunological characteristics and B cell subset distribution (IgD and CD27





















N. 32 29 20 41
Age, years 47.0 ± 15.2 61.5 ± 10.3 <0.001 0.92 (0.87-0.97) 50.2 ± 15.7 55.7 ± 14.3 0.21
Sex, n. female, n. (%) 26 (81.3) 26 (89.7) 0.36 16 (80.0) 36 (87.8) 0.42
VERA, n. (%) 13 (40.6) 9 (31.0) 0.44 11 (55.0) 11 (26.8) 0.03 8.89 (1.79-44.2)
Anti-TNF therapy 10 (31.3) 6 (20.7) 0.40 8 (40.0) 8 (19.5) 0.09
ESR, mm/1^hour 33.6 ± 23.2 54.0 ± 35.2 0.02 1.00 (0.96-1.04) 41.5 ± 30.3 54.0 ± 35.2 0.58
CRP, mg/l 11.3 ± 18.2 32.7 ± 45.9 0.01 0.98 (0.95-1.01) 18.7 ± 36.8 32.7 ± 45.9 0.23
DAS 3.1 ± 1.0 3.8 ± 1.1 0.05 0.58 (0.21-1.57) 3.2 ± 0.9 3.6 ± 1.1 0.13 0.34 (0.14-0.83)
CDAI 24.3 ± 12.4 28.7 ± 14.3 0.36 23.7 ± 11.4 27.7 ± 14.3 0.32
ACPA positivity, n. (%) 23 (71.9) 15 (51.7) 0.11 2.21 (0.57-8.66) 16 (80.0) 22 (53.7) 0.05 2.05 (0.36-11.6)
RF-IgM positivity, n. (%) 20 (62.5) 15 (51.7) 0.40 14 (70.0) 21 (51.2) 0.16
RF-IgA positivity, n. (%) 12 (37.5) 11 (37.9) 0.97 8 (40.0) 15 (36.6) 0.80
BAFF, pg/ml 878.3 ± 430.2 819.7 ± 265.3 0.77 991.0 ± 484.3 780.8 ± 264.1 0.08 1.002 (1.000-1.004)
IL6 (pg/ml) 13.4 ± 20.4 22.3 ± 24.8 0.02 1.02 (0.98-1.06) 18.0 ± 24.0 17.5 ± 22.5 0.79
CD19+/IgD + CD27+, % 8.3 ± 8.2 13.7 ± 18.7 0.25 7.3 ± 8.3 12.6 ± 16.3 0.08 1.03 (0.90-1.17)
CD19+/IgD + CD27-, % 67.5 ± 13.6 57.0 ± 17.2 0.01 1.06 (1.01-1.11) 68.7 ± 11.6 59.5 ± 17.3 0.03 1.09 (1.02-1.17)
CD19+/IgD-CD27+, % 15.2 ± 7.7 19.3 ± 8.8 0.08 1.06 (0.92-1.22) 14.6 ± 7.7 18.4 ± 8.5 0.09 1.09 (0.88-1.33)
CD19+/IgD-CD27-, % 7.2 ± 4.7 7.4 ± 4.2 0.58 7.7 ± 5.0 7.1 ± 4.2 0.47
CD19+/CD38 + CD27+, % 2.0 ± 2.1 3.1 ± 5.4 0.84 1.8 ± 1.4 2.9 ± 4.8 0.94
CD19+/ZAP70+, % 5.9 ± 7.4 4.1 ± 3.3 0.86 6.5 ± 8.1 4.3 ± 4.4 0.18
Values are mean ± standard deviation unless otherwise indicated. The values in bold are those that arose as significant in univariate and multivariate analyses.
ERA: early rheumatoid arthritis; LSRA: long-standing rheumatoid arthritis; VERA: very early rheumatoid arthritis; ESR: erythrocyte sedimentation rate; CRP: C-reactive
protein; DAS: disease activity score; ACPA: anti-citrullinated peptide antibodies; RF: rheumatoid factor.
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lower percentages and numbers of IgD and CD27 nega-
tive B cells and of plasmablasts (CD38 + CD27+).
The IgD + CD27- naïve B cells have been identified as
those likely containing auto-reactive B cells and carrying
predominantly auto-reactive B cell receptors [26]. There-
fore, it appears clear that the predominance of naïve B
cells in the early phases of the disease is biologically
relevant, particularly when devising a possible thera-
peutic strategy, since recently it has been shown in vitro
that Rituximab, a chimeric monoclonal antibody that
recognizes human CD20, inhibited the proliferation of
CD27- naïve, but not of CD27+ memory B cells [27].
Our results partially confirm recently published data
by Moura et al. on B cell subset distribution in a small
cohort of RA patients with a disease duration less than
six weeks. These authors observed lower percentages of
total memory B cells and higher percentages of naïve B
cells compared to controls [13].
In addition, our data suggest that the B cell biology is
strictly similar in VERA and ERA and that plasmablast
frequency is a marker of disease activity.When RA patients with a long-standing disease were
examined, higher percentages of switched-memory B
cells were observed and a strong correlation of this sub-
set with disease duration was found [10]. It has been hy-
pothesized that in LSRA patients the memory B cells
accumulated in the synovial compartment, probably
under the influence of TNF [10,11].
The lower percentage of circulating memory B cells
observed in VERA and ERA patients compared to LSRA
could be explained by the possible segregation of these
cells in the synovial compartment. The increase of naïve
activated cells could be reactive to the recruitment of
these cells in ectopic lymphoid tissue. The sequestration
of memory B cells in the synovium has been demon-
strated, recently, by our group, which found higher per-
centages of IgD-CD27+ and IgD-CD27- B cells and
lower percentages of naïve B cells in the synovial fluid
compared to the PB of patients with RA [25].
Interestingly, in this study, we found a lower percent-
age of memory B cells double negative for IgD and
CD27 in VERA and ERA compared to LSRA patients.
This cell subset is expanded in patients with systemic
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cantly with disease activity [28]. Therefore, we can
hypothesize that a major involvement of this B cell spe-
cific subpopulation could characterize the progression of
RA and the more severe forms of the disease, as it hap-
pens in SLE.
A possible clue to understand the compartmentalization
of B cell subsets could be related to the cytokine milieu
characteristic of the early phases of RA. The onset of the
disease is characterized by higher plasma levels of BAFF
and IL-6 compared to controls, as it has already been re-
ported [8,9,29,30].
The higher plasma IL-6 levels observed in patients
with VERA, support experimental data which describe
this cytokine among those that increase earlier and that
guide the transition from acute to chronic inflammation
[31]. Moreover, the early phases of the disease were
characterized by higher plasma BAFF levels compared to
LSRA patients, which positively correlate with the per-
centage of plasmablasts, of double negative memory B
cells and of B lymphocytes positive for ZAP-70, a pos-
sible biomarker of B cell activation.
Our group recently described higher percentages of
ZAP-70 positive B cells, exhibiting a memory/plasma-
blast phenotype, mostly in the aggregate pattern of syn-
ovial infiltrates and its value as a biomarker of activity
and efficacy in RA patients treated with B-cell depletion
therapy (BCDT) [25,32].
At the multivariate analysis, a younger age at diagno-
sis, “having VERA disease” and a higher frequency of
naïve B cells were significantly associated with remission
at 24 weeks of follow-up. These results confirmed our
previous data that VERA represents the best opportunity
to reach complete disease remission [12]. An interesting
finding of our study is that a higher percentage of the
naïve activated B cell subset (i.e. IgD + CD27-) at base-
line has emerged as a predictor of clinical remission. In
particular, patients with RA at onset with high percent-
ages of circulating naïve-activated B cells at baseline
(>60.0%) were 4 times more likely to achieve CDAI re-
mission after 24 weeks of treatment compared to pa-
tients with a low percentage of CD19+/IgD + CD27-.
Finally, the B-cell subsets were not affected by
DMARD therapy, thus raising the issue of which type of
remission is achieved. A limit of our study is the small
size of patients treated with anti-TNF that not allow to
assess whether this therapy influences the distribution of
B cell subsets over time.
Conclusions
In conclusion, the onset of RA is characterized by higher
percentages and absolute counts of naïve-activated B
cells and lower percentages and numbers of double
negative memory B cells and of plasmablasts, mostlyrelated to disease activity, compared to long-standing
RA. This could represent a more favorable biological set-
ting for therapies aiming at remission. The relationship
between some B cell phenotypes and remission, strongly
supports the rationale for studying activation and func-
tion of their different subsets.
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